Chugai Pharmaceutical Co., Ltd. (ADR)
General ticker "CHGCY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $84.8B (TTM average)
Chugai Pharmaceutical Co., Ltd. (ADR) follows the US Stock Market performance with the rate: 26.3%.
Estimated limits based on current volatility of 0.9%: low 24.71$, high 25.18$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-12-31, amount 0.41$ (Y1.62%)
- Price in estimated range
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [20.21$, 29.37$]
- 2026-12-31 to 2027-12-31 estimated range: [22.93$, 32.63$]
Financial Metrics affecting the CHGCY estimates:
- Positive: with PPE of 30.5 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 46.92 > 18.38
- Positive: 5.51 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: Inventory ratio change, % of 0.34 <= 0.80
- Positive: Interest expense per share per price, % of 0.01 <= 0.73
- Positive: Industry earnings per price (median), % of 5.49 > 4.48
- Negative: Operating cash flow per share per price, % of 2.99 <= 6.65
Short-term CHGCY quotes
Long-term CHGCY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | ¥1,111,367.00MM | ¥1,170,611.00MM | ¥1,318,925.14MM |
| Operating Expenses | ¥672,193.00MM | ¥628,609.00MM | ¥700,121.03MM |
| Operating Income | ¥439,174.00MM | ¥542,002.00MM | ¥618,804.11MM |
| Non-Operating Income | ¥4,647.00MM | ¥1,032.00MM | ¥7,984.17MM |
| Interest Expense | ¥0.00MM | ¥0.00MM | ¥1,075.74MM |
| R&D Expense | ¥174,868.00MM | ¥181,440.00MM | ¥196,692.63MM |
| Income(Loss) | ¥443,821.00MM | ¥543,034.00MM | ¥626,788.28MM |
| Taxes | ¥118,349.00MM | ¥155,717.00MM | ¥171,734.62MM |
| Profit(Loss)* | ¥325,472.00MM | ¥185,088.00MM | ¥455,052.61MM |
| Stockholders Equity | ¥1,625,580.00MM | ¥1,901,499.00MM | ¥2,027,114.84MM |
| Inventory | ¥273,480.00MM | ¥240,067.00MM | ¥277,036.99MM |
| Assets | ¥1,932,547.00MM | ¥2,208,373.00MM | ¥2,470,280.15MM |
| Operating Cash Flow | ¥409,925.00MM | ¥447,600.00MM | ¥408,331.32MM |
| Capital expenditure | ¥74,258.00MM | ¥54,899.00MM | ¥79,970.66MM |
| Investing Cash Flow | ¥-37,290.00MM | ¥-227,365.00MM | ¥-214,805.11MM |
| Financing Cash Flow | ¥-139,331.00MM | ¥-141,006.00MM | ¥-322,362.31MM |
| Earnings Per Share** | ¥98.90 | ¥56.24 | ¥138.26 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.